OBJECTIVES The aim of this study was to evaluate the choice of treatment for severe aortic valve stenosis in the era of transcatheter aortic valve replacement (TAVR) in Eastern Denmark.
replacement (TAVR). Since the first TAVR procedure performed by Cribier et al. (3) in 2002, the therapeutic management strategy for patients with severe AS has been revolutionized, especially for inoperable and high-risk patients (4) (5) (6) (7) . Recently, the number of TAVR procedures worldwide surpassed 200,000-the rate of TAVR is highest in Northwestern Europe with more than 50,000 TAVR procedures performed in Germany alone (8, 9) . In accordance, Scandinavian countries have been early adopters of this new technology and have played a pioneering role in introducing this technology to lower risk patients (10) . In this update, we study the choice of treatment for patients with severe AS in the era of TAVR in Eastern Denmark (2005 to 2015), with additional focus on the potential impact of TAVR on SAVR.
METHODS

In Eastern Denmark, all SAVR and TAVR procedures are registered in the WebPATS East Denmark Heart
Registry-registration is linked to reimbursement. All data are reported using standardized electronic data 
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The Kaplan-Meier survival analysis in Figure 5 indicates that TAVR is at least as safe as SAVR when However, this also implies that the data reported in this study are single-center data. Another potential limitation of this study is that the overall majority of patients were treated using self-expandable TAVR technology, with 75% of patients being treated with CoreValve (Medtronic, Minneapolis, Minnesota). REPRINT REQUESTS AND CORRESPONDENCE: Dr. Ole De Backer, The Heart Center, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. E-mail:
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